- Previous Close
1.4800 - Open
1.4500 - Bid 1.5800 x 100
- Ask 1.8200 x 100
- Day's Range
1.4500 - 1.6200 - 52 Week Range
1.4500 - 5.3400 - Volume
17,669,307 - Avg. Volume
15,187,645 - Market Cap (intraday)
1.013B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2700 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.50
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
www.geron.comRecent News: GERN
View MorePerformance Overview: GERN
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GERN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GERN
View MoreValuation Measures
Market Cap
942.62M
Enterprise Value
657.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.42
Price/Book (mrq)
3.36
Enterprise Value/Revenue
8.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-226.73%
Return on Assets (ttm)
-21.98%
Return on Equity (ttm)
-66.09%
Revenue (ttm)
76.99M
Net Income Avi to Common (ttm)
-174.57M
Diluted EPS (ttm)
-0.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
406.57M
Total Debt/Equity (mrq)
43.42%
Levered Free Cash Flow (ttm)
-137.23M